Identifying reliable biomarkers for AD, including blood-based markers, cerebrospinal fluid markers, and imaging biomarkers, is crucial for early detection, accurate diagnosis, and monitoring disease progression. Recently, the first Alzheimer's treatments targeting disease pathophysiology became available to patients and accelerated this need. Research is ongoing to develop new and more sensitive biomarkers that can detect AD pathology in its earliest stages, even before symptoms appear, when treatments are most effective. Non-invasive diagnostic tests are showing great promise in detecting β-amyloid and tau protein biomarkers equivalent or superior to FDA-approved CSF tests in the detection of AD pathology. These diagnostic assays, more easily accessible, will help alleviate the bottleneck and unmet needs of healthcare professionals and patients in evaluating them for AD.